Table I.
Clinical characteristics of the patients at the time of initiation of anakinra therapy
| Patient | Age | Sex | Disease duration |
Flare duration |
Fever/ rash |
Active arthritis |
Oral prednisone |
i.v. solumedrol |
MTX | Previous anti-TNF |
Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| mo | mo | (frequency) | mo | ||||||||
| Sys33 | 17 | F | 36 | 6 | Yes | Yes | Yes | Yes (q. 4 wk) | Yes | Yes | 12 |
| Sys47 | 9 | M | 29 | 12 | Yes | Yes | Yes | Yes (q. 2 wk) | No | No | 12 |
| Sys56 | 4 | F | 23 | 13 | Yes | Yes | Yes | Yes (q. 1 wk) | Yes | No | 8 |
| Sys2 | 12 | F | 125 | 125 | Yes | Yes | Yes | Yes (q. 4 wk) | Yes | Yes | 6 |
| Sys12 | 6 | F | 35 | 10 | Yes | No | Yes | Yes (q. 4 wk) | Yes | Yes | 6 |
| Sys15 | 4 | F | 30 | 30 | No | Yes | Yes | Yes (q. 4 wk) | No | Yes | 6 |
| Sys21 | 6 | F | 40 | 5 | Yes | Yes | Yes | Yes (q. 2 wk) | Yes | No | 4 |
| Sys38 | 4 | M | 38 | 18 | Yes | Yes | Yes | No | Yes | No | 4 |
| Sys25 | 14 | F | 144 | 30 | No | Yes | Yes | No | Yes | No | 2 |